Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European ...

The company states: “Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European Association of Urology congress, which data further ...

Primary investigator and presenter of the study, Ahmed H. Zedan, MD, PhD from Lillebaelt Hospital - University Hospital of Southern Denmark said: ”Proclarix can be safely used to reduce performed ...

Onconetix (ONCO) announced that an abstract has been accepted for presentation at the 2025 European Association of Urology, EAU, congress ...

Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has announced the presentation of new clinical data for Proclarix® during the 2025 European Association of Urology congress, showcasing its ...

Onconetix, Inc., formerly Blue Water Biotech, announced that an abstract has been accepted for presentation at the 2025 European Association of Urology congress in Madrid. The presentation will ...

A seasoned pharmaceutical executive joins Onconetix's top ranks as the downtown-based biotech company navigates yet another leadership change. STORY HIGHLIGHTS Onconetix's interim CEO Ralph ...

(MENAFN- GlobeNewsWire - Nasdaq) CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the“Company”), (formerly Blue ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer ...